A Study of TAK-676 and TAK-676 in Combination With Pembrolizumab in Adults With Advanced Solid Tumors

  • End date
    Mar 11, 2023
  • participants needed
  • sponsor
Updated on 12 May 2021


It is hoped that TAK-676, when given on its own or given with pembrolizumab will eventually help people with advanced or metastatic solid tumors.

The main aim of this study is to check if people with advanced solid tumors have side effects from TAK-676, and to check how much TAK-676 they can receive without getting side effects from it.

At the first visit, the study doctor will check who can take part. Participants will receive TAK-676 slowly through a vein (infusion). This will happen on 3 different days during a 21-day cycle. Different small groups of participants will receive lower to higher doses of TAK-676. Some participants will receive TAK-676 by itself and others will receive TAK-676 with pembrolizumab.

Participants will stay in the clinic or hospital for 24 hours after each infusion of TAK-676 in the first cycle of treatment. Sometimes the study doctor will carry out a physical exam before the participant goes home. Participants will be given an emergency card to carry with them at all times. The card has information about the study including contact details and a 24-hour emergency number.

Some participants, who receive TAK-676 and are willing and able, will be asked to wear a removable patch on their chest to record vital signs for 21 days in the first cycle of treatment. Also, in the first cycle of treatment, participants will record their oral temperatures twice a day for 21 days in a diary when they go home after each infusion.

Throughout treatment, the clinic will regularly telephone the participants to check on their health.

Condition Solid Neoplasms
Treatment Pembrolizumab, TAK-676
Clinical Study IdentifierNCT04420884
Last Modified on12 May 2021


Yes No Not Sure

Inclusion Criteria

Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
Life expectancy >12 weeks, as assessed by the investigator
TAK-676 SA
With histologically confirmed (cytological diagnosis is acceptable) advanced or metastatic solid tumors that have no standard therapeutic options or are intolerant to these therapies
TAK-676 in combination with pembrolizumab
With histologically confirmed (cytological diagnosis is acceptable) advanced or metastatic solid tumors that have no standard therapeutic options or are intolerant to them, including
Tumors that have relapsed or are refractory to anti-programmed cell death protein 1 (anti-PD-1)/anti-programmed cell death ligand 1 (anti-PD-L1) therapy
Tumors that are naive to anti-PD-1/ anti-PD-L1 therapy
Adequate bone marrow, renal, hepatic and cardiac functions
Left ventricular ejection fraction (LVEF) >50%, as measured by echocardiogram or multiple-gated acquisition (MUGA) scan within 4 weeks before receiving the first dose of study drug
Clinically significant toxic effects of previous therapy have recovered to Grade 1 (per NCI CTCAE Version 5.0) or baseline, except for alopecia, Grade 2 peripheral neuropathy, and/or autoimmune endocrinopathies with stable endocrine replacement therapy
Once peripheral evidence of TAK-676 pharmacodynamic stimulation of the innate and/or adaptive immune system is observed in the blood and/or clinical response/partial response (CR/PR) is observed in at least 1 participant, subsequent participants must
Have at least 1 lesion amenable for biopsy
Agree to have 2 tumor biopsies: 1 during the screening period and 1 while on TAK-676 treatment
Must have at least 1 RECIST v.1.1-evaluable (measurable or nonmeasurable) lesion
Pharmacokinetic (PK)/pharmacodynamic blood must be drawn on a peripherally-inserted catheter. TAK-676 is preferentially administered through a central line, but peripheral infusion is acceptable. If a peripheral line is used for TAK-676 and/or pembrolizumab infusion, it must be separate than the one used for PK/ pharmacodynamic collection

Exclusion Criteria

Corrected QT interval by Fredericia (QTcF) greater than (>) 450 milliseconds (men) or >475 milliseconds (women) on a 12-lead ECG during the screening period
Grade greater than or equal to (>=) 2 hypotension (that is, hypotension for which nonurgent intervention is required) at screening or during C1D1 predose assessment
Oxygen saturation less than (<) 92 percent (%) on room air at screening or during C1D1 predose assessment
Treated with other STING agonists/antagonist and toll-like receptors agonists within the past 6 months
Active vaping within 90 days of C1D1 of study drug(s)
Active smoking
Current history of pneumonitis, interstitial lung disease, severe chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, other restrictive lung diseases, acute pulmonary embolism, or Grade >=2 pleural effusion or ascites not controlled by tap or requiring indwelling catheters
History of brain metastasis unless
Clinically stable (that is, >=6 weeks) following prior surgery, whole-brain radiation, or stereotactic radiosurgery, AND
Off corticosteroids
Ongoing Grade >= 2 infection or participants with Grade >=2 fever of malignant origin
Chronic, active hepatitis (example: participants with known hepatitis B surface antigen seropositive and/or detectable hepatitis C virus [HCV]-RNA)
For participants in the SA arm only: refusal of standard therapeutic options
For participants in the combination arm only: contraindication and/or intolerance to the administration of pembrolizumab
Concurrent chemotherapy, immunotherapy (except for pembrolizumab in the combination arm), biologic, or hormonal therapy (except for adjuvant endocrine therapy for a history of breast cancer). Concurrent use of hormones for noncancer-related conditions is acceptable (except for corticosteroid hormones)
Radiation therapy within 14 days (42 days for radiation to the lungs) and/or systemic treatment with radionuclides within 42 days before C1D1 of study drug(s). Participants with clinically relevant ongoing pulmonary complications from prior radiation therapy are not eligible
Use of systemic corticosteroids or other immunosuppressive therapy, concurrently or within days of C1D1 of study drug(s), with the following exceptions
Topical, intranasal, inhaled, ocular, and/or intra-articular corticosteroids
Physiological doses of replacement steroid therapy (example: for adrenal insufficiency)
Use of medications that are known clinical OATP1B1 and/or OATP1B3 inhibitors, concurrently or within 14 days of C1D1 of study drug(s)
Receipt of live attenuated vaccine within 28 days of C1D1 of study drug(s)
Recipients of allogeneic or autologous stem cell transplantation or organ transplantation
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note